Skip to main content

Table 1 Sample summary and clinical results

From: Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

      

Pre-treatment

Post-treatment

Fold change

ID

TNM

Ki67

Grade

ER/PR

HER2

sTIL H&E (%)

sTIL mIF* (count/pixel)

PD-L1 mIF* (count/pixel)

PD-L1 SP142

sTIL H&E (%)

sTIL mIF* (count/pixel)

PD-L1 mIF* (count/pixel)

PD-L1 SP142

sTIL H&E

PD-L1 SP142

1

pT1c, N1

11%

2

+/+ (100%/100%)

–

8.75

0.48

0.07

IC0

12.5

0.59

0.13

IC0

+ 0.4

0

2

pT2c, pN2

19%

2

+/+ (96%/90%)

–

13.75

1.35

1.04

IC0

20

1.53

0.87

n/a

+ 0.5

n/a

3

pT2, N1

17%

2

+/+ (98%/100%)

–

1.75

0.13

0.07

IC0

1.75

1.25

0.35

IC1

0

+ 1

4

pT2N1

75%

3

−/− (0%/0%)

+

6.25

0.23

0.24

IC1

10

0.74

0.68

IC2

+ 0.6

+ 1

5

pT1c, N1

7%

1

+/+ (98%/92%)

–

3.75

0.88

0.18

IC0

5

0.34

0.09

IC1

+ 0.3

+ 1

6

T2, N1

73%

3

−/− (0%/0%)

+

18.75

0.84

0.01

IC0

18.75

0.94

0.40

IC0

0

0

7

T2, N1

55%

3

+/+ (98%/100%)

–

18.75

1.18

0.54

IC1

20

1.24

0.64

n/a

+ 0.1

n/a

8

pT2, N0

50%

3

+/+ (100%/42%)

–

7.5

1.28

0.97

IC1

16.25

1.68

1.30

IC1

+ 1.2

0

9

pT1b, pN0

11%

2

+/+ (100%/100%)

–

1

0.06

0.06

IC0

5

0.27

0.23

IC0

+ 4

0

10

T1c, N0

33%

2

+/+ (100%/99%)

–

11.5

0.41

0.38

IC1

18.75

1.48

1.33

IC3

+ 0.6

+ 2

11

pT1c, pN1a

38%

3

+/− (69%/0%)

+

6.25

0.35

0.22

IC1

5

1.59

0.65

IC2

−0.2

+ 1

12

pT2, N0

12%

3

+/+ (98%/100%)

+

61.25

2.21

1.81

IC1

72.5

3.52

1.99

IC3

+ 0.2

+ 2

13

pT2, pN0

87%

3

+/+ (100%/7%)

–

31.25

1.69

0.06

IC1

55

1.77

0.98

IC3

+ 0.8

+ 2

14

N/A

N/A

1

+/+ (100%/100%)

–

1

n/a

n/a

n/a

1

n/a

n/a

n/a

0

n/a

15

pT1c, N0

30%

2

+/+ (100%/50%)

–

3.5

1.26

n/a

IC0

7

1.14

0.76

IC2

+ 1

+ 2

16

pT1b, N0

95%

3

−/− (0%/0%)

–

1

0.38

0.03

IC0

13.75

0.99

0.06

IC3

+ 12.8

+ 3

  1. TNM stage by the TNM Classification of Malignant Tumors, Ki67% of Ki67-positive tumor cells, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, sTIL stromal tumor-infiltrating lymphocyte, H&E hematoxylin and eosin stain, PD-L1 programmed death ligand 1, SP142 Ventana PD-L1 assay, IC immune cell; *× 10−3